It's time to talk about

IBS-D MULTISYMPTOM RELIEF

for adult patients1-3

Short-term therapy

2 weeks of treatment for up to 6 months of relief of abdominal pain
and diarrhea1-3,*

Median of 10 weeks (range of 6 to 24 weeks).

Patients who experience recurrence can be retreated up to 2 times.

SEE CLINICAL DATA *See TARGET 1, 2, and 3 study data. 
Watch the
TV Spot Connect
With Us
Watch the TV Spot Connect With Us
icon gut icon gut

Gut dysbiosis and
IBS-D

GET THE FACTS
icon lookup icon lookup

Look up insurance
coverage

SEARCH NOW
icon saving icon saving

Instant Savings Card
available

GET DETAILS

#1 prescribed medication approved for IBS-D4

Based on aggregated total of all prescribers as of August 2024.

Is now a good time to watch our commercial?

This TV spot may have patients asking about XIFAXAN. See what they’re talking about.

SEE MORE FROM YOUR PEERS & PATIENTS
Insurance Coverage Resources Insurance Coverage Resources

Insurance Coverage Resources

Learn how QSA can support your patients and practice.

GET XIFAXAN QSA
IBS-D Clinical Resources IBS-D Clinical Resources

IBS-D Clinical Resources

Get perspectives from your peers, tools, and educational material on diagnosis and treatment of IBS-D.

VISIT GASTROHUB
XIFAXAN Strong Recommendation Seal

Now is a good time to talk about treatment

XIFAXAN was given a strong recommendation† to treat global IBS-D symptoms

In the 2020 American College of Gastroenterology (ACG) Clinical Guideline on Managing IBS5,‡

‡Based on a moderate quality of evidence. §

†Strength of recommendation: Strong=Most patients should receive the recommended course of action. Conditional=Many patients should have this recommended course of action, but different choices may be appropriate for some patients.
§Summary of quality of evidence: High=The estimate of effect is unlikely to change with new data. Moderate=The estimate of effect is uncertain.

IBS-D, irritable bowel syndrome with diarrhea.

See More

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
See Less

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    – HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
    – IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

References: 1. XIFAXAN. Prescribing information. Salix Pharmaceuticals; 2023. Accessed November 27, 2024. https://shared.salix.com/globalassets/pi/xifaxan550-pi.pdf 2. Pimentel M, Lembo A, Chey WD, et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32. doi:10.1056/NEJMoa1004409 3. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113-1121. doi:10.1053/j.gastro.2016.08.003 4. Data on file. LAAD August 2024. Salix Pharmaceuticals, Bridgewater, NJ. 5. Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg

XIFI.0121.USA.23V3.0